OSE Immunotherapeutics SA Sustainability Profile
OSE Immunotherapeutics SA, headquartered in France, is a pioneering biotechnology company specialising in immunotherapy solutions for cancer and autoimmune diseases. Founded in 2012, OSE has rapidly established itself as a leader in the biopharmaceutical industry, focusing on the development of innovative therapeutic products that harness the body’s immune system. The company’s core offerings include a diverse pipeline of monoclonal antibodies and vaccine candidates, distinguished by their unique mechanisms of action. Notable achievements include strategic partnerships and collaborations that enhance its market position, particularly in Europe and North America. OSE Immunotherapeutics is committed to advancing the frontiers of immunotherapy, aiming to provide effective treatments that address unmet medical needs in oncology and beyond.
DitchCarbon Score
How does OSE Immunotherapeutics SA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
OSE Immunotherapeutics SA's score of 29 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
OSE Immunotherapeutics SA's reported carbon emissions
OSE Immunotherapeutics SA, headquartered in France, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. Consequently, there are no recorded Scope 1, 2, or 3 emissions to analyse. Additionally, the company has not established any documented reduction targets or climate pledges, which limits the available information on their climate commitments. In the context of the industry, it is essential for companies like OSE Immunotherapeutics SA to develop and implement robust climate strategies to address the growing concerns around carbon emissions and sustainability. As of now, the lack of emissions data and reduction initiatives suggests an opportunity for the company to enhance its environmental accountability and align with industry standards for climate action.
How Carbon Intensive is OSE Immunotherapeutics SA's Industry?
How Carbon Intensive is OSE Immunotherapeutics SA's Location?
OSE Immunotherapeutics SA's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
OSE Immunotherapeutics SA has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
